Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. - Wikidata - awgldk - TriplyDB

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q34438769

about

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

P2860

Q28074843-C3E65DD3-9CE1-42ED-9E87-BBFAF0E28A6B Q34439528-29876BEA-D8A3-4929-B909-DDC22CDA319E Q38569449-7EECEF71-E719-43C9-8657-7614593F3069 Q38762808-F042070A-2D4C-40DC-90B9-B3A065AA5F67 Q38908779-CD5B6A58-6B28-456D-A933-DFBC6F533ACF Q42107886-E5E32899-F6B5-4E40-BAB5-3A62CC49FBCB

P2860

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q34438769

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized trial showing effic ...... treatment of type 2 diabetes.

@ast

Randomized trial showing effic ...... treatment of type 2 diabetes.

@en

Randomized trial showing effic ...... treatment of type 2 diabetes.

@nl

type

label

Randomized trial showing effic ...... treatment of type 2 diabetes.

@ast

Randomized trial showing effic ...... treatment of type 2 diabetes.

@en

Randomized trial showing effic ...... treatment of type 2 diabetes.

@nl

prefLabel

Randomized trial showing effic ...... treatment of type 2 diabetes.

@ast

Randomized trial showing effic ...... treatment of type 2 diabetes.

@en

Randomized trial showing effic ...... treatment of type 2 diabetes.

@nl

P1433

Q34438769-9C197EB3-E6B9-4F76-A892-B3E7AC901FD1

P1476

Q34438769-837BDD0F-5F2E-41F8-834C-BB837FDC98A5

P2093

Q34438769-0F1CB58E-D5FE-4F25-BF34-1CA1C189CDB3

Q34438769-2700BC04-26FC-4046-8DBB-497E78C851A2

Q34438769-9467D7EB-7D18-4545-BF07-A289DB9723AF

Q34438769-CC7FC4EB-1C20-43D0-AFC3-B1B1475A27DD

Q34438769-E4091407-3E64-49EF-9AE2-919BB069ED00

Q34438769-F4B40A59-2902-4B6C-8706-2AC6A3E7BC1F

Q34438769-FDEE96A8-0A8B-4DB7-AFF6-7FD14FE30771

Q34438769-FF8AE945-D804-4FEB-9AE4-5BB8880724ED

P2860

Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51B

Q34438769-0B7C1323-1ACC-4A61-B135-52D1E952DB19

Q34438769-119693DF-329E-49C3-8124-7DECDDA35B18

Q34438769-1F842653-27D7-4FFA-8013-33D1DF1B1617

Q34438769-21DB57B4-E16B-4FC5-95A7-859549729975

Q34438769-45A18306-3860-4961-AD94-2EF482445503

Q34438769-65DA39B7-B89C-4001-A208-AF57E3106B44

Q34438769-7D92A2B9-35A5-4AFA-8A30-59A19F0F4607

Q34438769-877672CC-7458-4A2A-80F5-F9667C1D1FCA

Q34438769-D80B843E-F7DB-4E76-B0F4-7CB81B31756A

P304

Q34438769-97E71D3E-487F-4B37-85B9-04EE9F309666

P31

Q34438769-5802DD44-87AF-4B87-BED1-14D0BEAFDE29

P356

Q34438769-3489FEF4-E007-4916-AD05-60293C3D563B

P433

Q34438769-29521A6D-9B87-46FA-93C6-D53CB895D865

P478

Q34438769-8EA76FF7-1695-405D-A6F8-C23B46B96F55

P577

Q34438769-C1A69213-571A-4142-99B6-E544EE4F0106

P698

Q34438769-95F664AF-498C-447A-A179-6F84164DEB9C

P921

Q34438769-71737E16-8575-4870-8DA1-A7577B30B7AC

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Randomized trial showing effic ...... treatment of type 2 diabetes.

@en

P2093

A P Sykes

http://www.w3.org/2001/XMLSchema#string

D J Dorey

http://www.w3.org/2001/XMLSchema#string

J D Lorimer

http://www.w3.org/2001/XMLSchema#string

L Kler

http://www.w3.org/2001/XMLSchema#string

R Dobbins

http://www.w3.org/2001/XMLSchema#string

R O'Connor-Semmes

http://www.w3.org/2001/XMLSchema#string

S Walker

http://www.w3.org/2001/XMLSchema#string

W O Wilkison

http://www.w3.org/2001/XMLSchema#string

P2860

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Hypertriglyceridaemia in diabetes.

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis.

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.

Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation?

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

P304

94-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12391

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25223369

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes